Literature DB >> 6097468

Characteristics of polymorphonuclear leukocyte infiltration into the alkali burned eye and the influence of sodium citrate.

C A Paterson, R N Williams, A V Parker.   

Abstract

Polymorphonuclear leukocytes (PMNs) are considered to play a central role in the corneal ulceration process subsequent to an alkali burn. We have described the time course of PMN infiltration into the ocular tissues following an alkali burn. In addition, we examined the effect of sodium citrate upon the accumulation of PMNs in the alkali burned cornea. The accumulation of PMNs into the cornea and iris-ciliary body was quantified by measuring myeloperoxidase (MPO), an enzyme marker for these inflammatory cells. Leukocytes in aqueous humor aspirates and corneal washes were counted directly under a microscope. In the alkali burned cornea, we found an initial transient, yet substantial, infiltration of PMNs, peaking at about 12-24 hr and limited to the peripheral cornea; this subsided by about 72 hr. By 14 days, the MPO activity, and hence the number of leukocytes, had risen again, and by 21 days the level had increased by several fold. Qualitatively similar biphasic patterns of leukocyte infiltration were observed in the iris-ciliary body and aqueous humor. Leukocyte numbers in corneal washes only increased between 4-24 hr following the alkali burn. The exceptionally high degree of leukocyte infiltration into the cornea at 21 days corresponded with the presence of ulceration. Topical administration of sodium citrate (10%) inhibited the early and late phase of PMN accumulation in the alkali burned cornea, i.e. at 24 hr (-63%) and 21 days (-92%). The inhibition of PMN infiltration by sodium citrate correlates with the reduced corneal ulceration observed following treatment with this compound.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6097468     DOI: 10.1016/0014-4835(84)90069-1

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  7 in total

1.  Proteomic analyses of corneal tissue subjected to alkali exposure.

Authors:  Toral Parikh; Natalie Eisner; Praseeda Venugopalan; Qin Yang; Byron L Lam; Sanjoy K Bhattacharya
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-01       Impact factor: 4.799

2.  Differential Effects of Dexamethasone and Doxycycline on Inflammation and MMP Production in Murine Alkali-Burned Corneas Associated with Dry Eye.

Authors:  Fang Bian; Flavia S A Pelegrino; Johanna Tukler Henriksson; Stephen C Pflugfelder; Eugene A Volpe; De-Quan Li; Cintia S de Paiva
Journal:  Ocul Surf       Date:  2016-01-06       Impact factor: 5.033

3.  The spatio-temporal dynamics of ligament healing.

Authors:  Connie S Chamberlain; Erin Crowley; Ray Vanderby
Journal:  Wound Repair Regen       Date:  2009 Mar-Apr       Impact factor: 3.617

4.  Effect of vasoactive intestinal peptide on the wound healing of alkali-burned corneas.

Authors:  Nese Tuncel; Nilgun Yildirim; Firdevs Gurer; Hikmet Basmak; Kubilay Uzuner; Varol Sahinturk; Huseyin Gursoy
Journal:  Int J Ophthalmol       Date:  2016-02-18       Impact factor: 1.779

5.  Amniotic membrane traps and induces apoptosis of inflammatory cells in ocular surface chemical burn.

Authors:  Ting Liu; Hualei Zhai; Yuanyuan Xu; Yanling Dong; Yajie Sun; Xinjie Zang; Jing Zhao
Journal:  Mol Vis       Date:  2012-07-26       Impact factor: 2.367

6.  A Novel Therapeutic Approach to Corneal Alkaline Burn Model by Targeting Fidgetin-Like 2, a Microtubule Regulator.

Authors:  Jessie Wang; Abhinav Dey; Adam H Kramer; Yuan Miao; Juan Liu; Lisa Baker; Joel M Friedman; Parimala Nacharaju; Roy S Chuck; Cheng Zhang; David J Sharp
Journal:  Transl Vis Sci Technol       Date:  2021-01-08       Impact factor: 3.283

7.  An ophthalmic solution of a peroxisome proliferator-activated receptor gamma agonist prevents corneal inflammation in a rat alkali burn model.

Authors:  Masaaki Uchiyama; Akira Shimizu; Yukinari Masuda; Shinya Nagasaka; Yuh Fukuda; Hiroshi Takahashi
Journal:  Mol Vis       Date:  2013-11-01       Impact factor: 2.367

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.